MA40182A - NOUVEL ANTICORPS ANTI-Tie2 HUMAIN - Google Patents

NOUVEL ANTICORPS ANTI-Tie2 HUMAIN

Info

Publication number
MA40182A
MA40182A MA040182A MA40182A MA40182A MA 40182 A MA40182 A MA 40182A MA 040182 A MA040182 A MA 040182A MA 40182 A MA40182 A MA 40182A MA 40182 A MA40182 A MA 40182A
Authority
MA
Morocco
Prior art keywords
chain variable
variable regions
human tie2
amino acid
heavy chain
Prior art date
Application number
MA040182A
Other languages
English (en)
Inventor
Yoshinori Ishii
Masazumi Kamohara
Hiromi Nara
Shigenori Yagi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MA40182A publication Critical patent/MA40182A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)

Abstract

L'invention concerne un anticorps anti-tie2 humain qui prévient ou traite l'œdème maculaire diabétique, la rétinopathie diabétique ou l'ischémie critique de membre inférieur en se liant au tie2 humain et en activant le tie2 humain. Les auteurs de la présente invention ont étudié les anticorps anti-tie2 humain et ont fourni un anticorps anti-tie2 humain comprenant quatre régions variables de chaîne lourde et quatre régions variables de chaîne légère. Les régions variables de chaîne lourde comprennent une séquence d'acides aminés provenant de l'acide aminé n°1 à 122 de la seq id no:2, et les régions variables de chaîne légère comprennent une séquence d'acides aminés provenant de l'acide aminé n°1 à 113 de seq id no:4. L'une des régions variables de chaîne lourde et l'une des régions variables de chaîne légère constituent un site de liaison à l'antigène, et l'anticorps comprend quatre sites de liaison à l'antigène.
MA040182A 2014-07-15 2015-07-14 NOUVEL ANTICORPS ANTI-Tie2 HUMAIN MA40182A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014145135 2014-07-15

Publications (1)

Publication Number Publication Date
MA40182A true MA40182A (fr) 2017-05-24

Family

ID=55078504

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040182A MA40182A (fr) 2014-07-15 2015-07-14 NOUVEL ANTICORPS ANTI-Tie2 HUMAIN

Country Status (18)

Country Link
US (2) US9683051B2 (fr)
EP (1) EP3170841A4 (fr)
JP (2) JP6699551B2 (fr)
KR (1) KR102455680B1 (fr)
CN (1) CN106687478B (fr)
AR (1) AR101202A1 (fr)
AU (1) AU2015290673B2 (fr)
BR (1) BR112017000689A2 (fr)
CA (1) CA2954754C (fr)
IL (1) IL249964B (fr)
MA (1) MA40182A (fr)
MX (1) MX2017000615A (fr)
MY (1) MY185811A (fr)
PH (1) PH12017500094A1 (fr)
RU (1) RU2702553C2 (fr)
SG (1) SG11201700271RA (fr)
TW (1) TWI685502B (fr)
WO (1) WO2016010014A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226750A1 (fr) * 2017-06-06 2018-12-13 Relinia, Inc. Protéines de fusion agonistes du récepteur 2 du tnf monocaténaire
AU2019232523A1 (en) * 2018-03-05 2020-09-03 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
WO2019235856A1 (fr) * 2018-06-07 2019-12-12 기초과학연구원 Anticorps se liant à tie2 et son utilisation
CA3113059A1 (fr) 2018-09-21 2020-03-26 The University Of North Carolina At Chapel Hill Agents de liaison synthetiques permettant de limiter la permeation a travers le mucus
US20220213201A1 (en) * 2019-08-14 2022-07-07 Pharmabcine Inc. Anti-tie2 antibody and use thereof
KR20220131894A (ko) * 2019-11-21 2022-09-29 유니티 바이오테크놀로지, 인크. Tie-2에 지향성인 항체 및 사용 방법
CN115867649A (zh) * 2020-03-24 2023-03-28 基因泰克公司 Tie2结合剂及其使用方法
KR20220059924A (ko) * 2020-11-03 2022-05-10 한국생명공학연구원 신규 항-Tie2 항체 또는 이의 항원 결합 단편, 및 이의 용도
EP4335871A1 (fr) * 2021-05-06 2024-03-13 Institute for Basic Science Anticorps agonistes de tie2 et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
PL357939A1 (en) * 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US9758594B2 (en) * 2008-04-25 2017-09-12 Kyowa Hakko Kirin Co., Ltd. Stable multivalent antibody
CA2818215C (fr) * 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions et methodes de traitement d'un oedeme oculaire, de neovascularisation et de maladies associees
CN103874709B (zh) 2011-08-19 2016-12-21 瑞泽恩制药公司 抗tie2抗体及其用途
CA2876099A1 (fr) * 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Procede de production de molecules monomeres et multimeres et leurs utilisations

Also Published As

Publication number Publication date
IL249964A0 (en) 2017-03-30
BR112017000689A2 (pt) 2018-01-23
TW201617366A (zh) 2016-05-16
RU2017104642A (ru) 2018-08-15
AR101202A1 (es) 2016-11-30
US9683051B2 (en) 2017-06-20
WO2016010014A1 (fr) 2016-01-21
CN106687478B (zh) 2020-08-28
CN106687478A (zh) 2017-05-17
CA2954754C (fr) 2023-01-17
JP6699551B2 (ja) 2020-05-27
RU2017104642A3 (fr) 2019-03-07
JP2020103302A (ja) 2020-07-09
AU2015290673A1 (en) 2017-02-02
TWI685502B (zh) 2020-02-21
MX2017000615A (es) 2017-05-01
KR102455680B1 (ko) 2022-10-17
US20160222130A1 (en) 2016-08-04
CA2954754A1 (fr) 2016-01-21
RU2702553C2 (ru) 2019-10-08
AU2015290673B2 (en) 2020-10-29
US20170253669A1 (en) 2017-09-07
JP6860103B2 (ja) 2021-04-14
US9902782B2 (en) 2018-02-27
IL249964B (en) 2020-11-30
EP3170841A4 (fr) 2018-01-10
EP3170841A1 (fr) 2017-05-24
KR20170029508A (ko) 2017-03-15
PH12017500094A1 (en) 2017-05-22
JPWO2016010014A1 (ja) 2017-04-27
SG11201700271RA (en) 2017-04-27
MY185811A (en) 2021-06-10

Similar Documents

Publication Publication Date Title
PH12017500094A1 (en) Novel anti-human tie-2 antibody
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
NZ706377A (en) Il-6 antagonists and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MD20170031A2 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
EA201492282A1 (ru) Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
PE20190737A1 (es) Anticuerpos anti-cd27
MX2021008663A (es) Anticuerpos mejorados contra il-6.
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
MX2019009377A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
JOP20190103B1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
EA201992460A1 (ru) Антитела-агонисты btla и их применение
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
BR112018068637A2 (pt) podocalixina e anticorpo relacionado a tra, métodos de preparação e usos como agente terapêutico anticancerígeno
TR201901045T4 (tr) İnsan TLR2 ve insan TLR4'e bağlanan yeni bispesifik antikor.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения